Spark Therapeutics, Inc. Overview
Pro stress-test →Spark Therapeutics is a developer of gene therapy for rare diseases. The company was acquired by Roche on December 17, 2019 and now operates as an independent subsidiary within the Roche Group. The company focuses on treating orphan diseases, with a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.
Strategic Profile
Pro stress-test →Spark is investing $575M to build a Gene Therapy Innovation Center in Philadelphia, projected for completion in 2026. As a Roche subsidiary, the facility will serve as a global centre of excellence for gene therapy. One of its key products, Fidanacogene elaparvovec, received FDA approval in 2024.
Competitive Landscape
Pro stress-test →Spark competes in the specialized gene therapy market targeting rare genetic diseases. Top competitors include Moderna, BridgeBio and Exact Sciences. Additional competitors include Strand Therapeutics, Atsena Therapeutics, and Spur Therapeutics. As a Roche subsidiary with approved products and substantial manufacturing infrastructure investment, Spark holds a differentiated position in rare disease gene therapy.
Industry Context
Spark Therapeutics, Inc. operates in Gene therapy for rare genetic diseases.
Key facts
Founded: 2013 · Headquarters: Philadelphia, US · Employees: N/A · Revenue: N/A · Market cap: N/A